Providing the full picture: A mandate for standardizing nanoparticle-based drug delivery

Nanomedicine

Volumn 8, Issue 7, 2013, Pages 1031-1033

  Howard, Kenneth A ^a   Peer, Dan ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

drug delivery; nanoparticles; physicochemical characterization; standardization; structural characterization; surface characterization

Indexed keywords

NANOPARTICLE;

ATOMIC FORCE MICROSCOPY; CELL INTERACTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; LIGHT SCATTERING; MACROPHAGE; MASS SPECTROMETRY; NONHUMAN; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; X RAY PHOTOELECTRON SPECTROSCOPY;

EID: 84879626081     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.95     Document Type: Review

References (22)

1. Pedersen MB, Zhou X, Larsen EK et al. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol. 184, 1931-1945 (2010).
2. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867-6875 (2010).
3. Peer D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 64, 1738-1748 (2012).
4. Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J. Control. Release 161, 600-608 (2012).
5. Peer D. A daunting task: manipulating leukocyte function with RNAi. Immunol. Rev. 253, 185-197 (2013).
6. Moyano DF, Goldsmith M, Solfiell DJ et al. Nanoparticle hydrophobicity dictates immune response. J. Am. Chem. Soc. 134, 3965-3967 (2012).
7. Ebbesen MF, Whitehead B, Ballarin-Gonzalez B, Kingshott P, Howard KA. Surface analysis of PEGylated nano-shields on nanoparticles installed by hydrophobic anchors. Pharm. Res. doi:10.1007/s11095-013-1018-3 (2013) (Epub ahead of print).
8. Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 27, 796-810 (2010).
9. Howard KA, Rahbek UL, Liu X et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476-484 (2006). (Pubitemid 44296092)
10. Liu X, Howard KA, Dong M et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28, 1280-1288 (2007). (Pubitemid 44816373)
11. Howard KA, Dong M, Oupicky D et al. Nanocarrier stimuli-activated gene delivery. Small 3, 54-57 (2007). (Pubitemid 46114264)
12. Rahbek UL, Howard KA, Oupicky D et al. Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J. Gene Med. 10, 81-93 (2008).
13. Kirchhausen T, Boll W, van Oijen A, Ehrlich M. Single-molecule live-cell imaging of clathrin-based endocytosis. Biochem. Soc. Symp. 72, 71-76 (2005). (Pubitemid 44804736)
14. Akinc A, Querbes W, De S et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357-1364 (2010).
15. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839-850 (2006). (Pubitemid 43779110)
16. Newton AJ, Kirchhausen T, Murthy VN. Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis. Proc. Natl Acad. Sci. USA 103, 17955-17960 (2006). (Pubitemid 44852267)
17. Larsen EK, Nielsen T, Wittenborn T et al. Size-dependent accumulation of PEGylated silane-coated magnetic iron oxide nanoparticles in murine tumors. ACS Nano 3, 1947-1951 (2009).
18. Nawroth I, Alsner J, Deleuran BW et al. Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model. Acta Oncol. doi:10.3109/0284186X.2012.726373 (2012) (Epub ahead of print).
19. Szebeni J, Moghimi SM. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J. Liposome Res. 19, 85-90 (2009).
20. Andersen AJ, Hashemi SH, Andresen TL, Hunter AC, Moghimi SM. Complement: alive and kicking nanomedicines. J. Biomed. Nanotechnol. 5, 364-372 (2009).
21. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627-630 (2008). (Pubitemid 351197066)
22. Akinc A, Goldberg M, Qin J et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 17(5), 872-879 (2009).